The Heartmate Risk Score predicts morbidity and mortality in unselected left ventricular assist device recipients and risk stratifies INTERMACS class 1 patients.

ABSTRACT:

Objectives

This study evaluated the Heartmate Risk Score (HMRS) and its potential benefits in clinical practice.

Background

The HMRS has been shown to correlate with mortality in the cohort of patients enrolled in the Heartmate II trials, but its validity in unselected, "real world" populations remains unclear.

Methods

This study identified a cohort of 269 consecutive patients who received a Heartmate II left ventricular assist device at our institution, the Barnes-Jewish Hospital in St. Louis, Missouri, between June 2005 and June 2013. Ninety-day and 2-year mortality rates, as well as frequency of several morbid events, were compared by retrospectively assigned HMRS category groups. The analysis was repeated within the subgroup of INTERMACS (Interagency Registry for

SUBMITTER: Adamo L 

PROVIDER: S-EPMC4767256 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature